Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.

PloS one - 1 Jan 2015

Pereira Elena, Camacho-Vanegas Olga, Anand Sanya, Sebra Robert, Catalina Camacho Sandra, Garnar-Wortzel Leopold, Nair Navya, Moshier Erin, Wooten Melissa, Uzilov Andrew, Chen Rong, Prasad-Hayes Monica, Zakashansky Konstantin, Beddoe Ann Marie, Schadt Eric, Dottino Peter, Martignetti John A

Abstract excerpt

BACKGROUND: High-grade serous ovarian and endometrial cancers are the most lethal female reproductive tract malignancies worldwide. In part, failure to treat these two aggressive cancers successfully centers on the fact that while the majority of patients are diagnosed based on current surveillance strategies as having a complete clinical response to their primary therapy, nearly half will develop disease...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to CA-125 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to Endometrial Neoplasms

Share to Genital Neoplasms, Female

Share to Neoplasm Recurrence, Local

Share to Ovarian Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 26717006
DOI: 10.1371/journal.pone.0145754
PMCID: PMC4696808

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.PMID 26717006Read ↗

Selective utilization of circulating tumor DNA testing enables disease monitoring in endometrial and ovarian carcinomas.Semantic proximity Read ↗

Circulating Tumor DNA (ctDNA) and Its Role in Gynecologic Malignancies.Semantic proximity Read ↗

Sensitive Detection of Gynecological Cancer Recurrence Using Circulating Tumor DNA and Digital PCR: A Comparative Study with Serum Biochemical Markers.Semantic proximity Read ↗

Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.Semantic proximity Read ↗

Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.Semantic proximity Read ↗

Circulating tumor DNA as a prognostic marker in high-risk endometrial cancerSemantic proximity Read ↗

Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.Semantic proximity Read ↗

Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian Cancer.Semantic proximity Read ↗

Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients.Semantic proximity Read ↗

Utility of Circulating Tumor DNA for Detection and Monitoring of Endometrial Cancer Recurrence and ProgressionSemantic proximity Read ↗

Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancerSemantic proximity Read ↗

Utility of circulating tumor DNA for detection and monitoring of endometrial cancer recurrence and progressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.